SecurityAY / Atlantica Yield plc (G00349103)
Institutional Owners4
Institutional Shares118,760
Institutional Value$ 2,396,000 USD

Institutional Stock Ownership and Shareholders()

AY / Atlantica Yield plc Institutional Ownership

Atlantica Yield plc (NASDAQ:AY) has 4 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 118,760 shares. Largest shareholders include A. D. Beadell Investment Counsel, Inc., JP Morgan Chase & Co, Group One Trading, L.p., and Simplex Trading, Llc.
Atlantica Yield plc (NASDAQ:AY) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/ay"><img src="https://images.fintel.io/us-ay-so.png" alt="AY / Atlantica Yield plc Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-10 13F-HR JP Morgan Chase & Co Call 100,000 100,000 0.00 2,121 1,958 -7.69
2018-04-26 13F-HR SIMPLEX TRADING, LLC Call 300 337 12.33 59 21 -64.41
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Call 20,000 30,700 53.50 424 601 41.75
2018-07-19 13F-HR A. D. Beadell Investment Counsel, Inc. 118,110 118,760 0.55 2,312 2,396 3.63

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Buy 5 Defensive Stocks as US-China Trade Conflicts Intensify

2018-07-19 investorplace
The trade conflict between the United States and China, which commenced March, is further intensifying as days progress. The U.S. stock markets have been facing severe volatility ever since primarily owing to imposition of various tariffs by the U.S. government and related trade conflict.

SCANA & Dominion Energy's Merger Deal Gets FERC Approval

2018-07-16 zacks
SCANA Corporation’s (SCG - Free Report) proposed merger with Dominion Energy, Inc. (D - Free Report) recently received an important approval from the Federal Energy Regulatory Commission (FERC), which declared the deal to be consistent with public interest. (1-0)

Looking For A Utility With Growth? Algonquin Is For You

2018-07-16 seekingalpha
Algonquin (AQN) is a fairly unknown utility; based in Canada, it has a mid-sized market capitalization of only $4.54 billion. With operations expanding throughout the United States, Canada, and many other countries, Algonquin is the only utility in my portfolio due to its ability to keep growing and offering attractive shareholder returns. Management has been delivering strong dividend and revenue growth and has a plan to keep doing so. (1-0)

5 Reasons to Add Algonquin Power (AQN) to Your Portfolio Now

2018-07-12 zacks
Algonquin Power & Utilities Corp.’s (AQN - Free Report) earnings estimates have been revised upward over the past 60 days, reflecting analysts’ confidence in the stock. The Zacks Consensus Estimate for 2018 and 2019 earnings has moved 8.2% and 5.3% north to 66 cents and 60 cents per share, respectively, within the same time frame. Algonquin Power & Utilities, currently a Zacks Rank #1 (Strong Buy) stock, is the owner and operator of a portfolio of regulated and non-regulated generation, distribution, and transmission utility assets. (1-0)

World Cup Success, GDP Growth Boost U.K. Economy: 5 Picks

2018-07-11 zacks
The FIFA World Cup in Russia witnessed many surprises this time, including the defending champion Germany’s early exit. While some other favorites followed suit, team England gave a stunning performance, its best since the 1990 World Cup. A great world cup season helped boost U.K. stocks considerably. Additionally, Bank of England said that this World Cup will actually help Britain overcome the Brexit-related tensions.

CUSIP: G00349103